Linagliptin: Perbedaan antara revisi
Konten dihapus Konten ditambahkan
←Membuat halaman berisi '{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 452028402 | IUPAC_name = 8-[(3''R'')-3-Aminopiperidin-1-il]-7-(but-2-in-1-il)-3-metil-1-[(4-metilkuinazolin-2-il)metil]-3,7-dihidro-1''H''-purina-2,6-diona | image = Linagliptin.svg | width = 250 | alt = <!--Clinical data--> | pronounce = {{IPAc-en|ˌ|l|ɪ|n|ə|ˈ|g|l|ɪ|p|t|ɪ|n}} {{respell|LIN|ə|GLIP|tin}} | tradename = Tradjenta, Trajenta, Trazenta | Drugs.com = {{drugs.com|mon...' Tag: Suntingan perangkat seluler Suntingan peramban seluler Suntingan seluler lanjutan |
k clean up |
||
| (10 revisi perantara oleh satu pengguna lainnya tidak ditampilkan) | |||
Baris 6:
| image = Linagliptin.svg
| width = 250
| alt =
<!--Clinical data-->
Baris 19:
| ATC_prefix = A10
| ATC_suffix = BH05
| ATC_supplemental =
| legal_AU = S4
Baris 34:
<!--Pharmacokinetic data-->
| bioavailability = ~30% ([[Cmax
| protein_bound = 75–99% (
| metabolism = Minimal (~10% dimetabolisme)
| metabolites =
| elimination_half-life = ~24 jam
| excretion = [[Feses]] (80%), [[urin]] (5%)<ref name="Tradjenta FDA label" />
Baris 70:
}}
'''Linagliptin''' adalah obat yang digunakan untuk mengobati [[diabetes melitus tipe 2]] bersamaan dengan olahraga dan diet.<ref name=AHFS2019/><ref name="Neumiller_2012">{{cite journal | vauthors = Neumiller JJ | title = Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus | journal = The Annals of Pharmacotherapy | volume = 46 | issue = 3 | pages = 358–67 | date = March 2012 | pmid = 22318932 | doi = 10.1345/aph.1Q522 | s2cid = 207264493 }}</ref> Linagliptin termasuk dalam kelas obat yang disebut penghambat DPP-4.<ref name="Tradjenta FDA label">{{cite web | title=Tradjenta- linagliptin tablet, film coated | website=DailyMed | date=21 April 2022 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c797ea5c-cab7-494b-9044-27eba0cfe40f | access-date=3 October 2022 | archive-date=15 August 2022 | archive-url=https://web.archive.org/web/20220815101823/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c797ea5c-cab7-494b-9044-27eba0cfe40f | url-status=live }}</ref> Obat ini secara umum kurang disukai dibandingkan [[metformin]] dan [[sulfonilurea]] sebagai pengobatan awal.<ref name=
[[Efek samping]] yang umum termasuk radang hidung dan tenggorokan. Efek samping yang serius mungkin termasuk [[edema angioneurotik|angioedema]], [[pankreatitis]], nyeri sendi.<ref name=
Linagliptin telah disetujui untuk penggunaan medis di Amerika Serikat,<ref>{{cite web | title=Drug Approval Package: Tradjenta (linagliptin) Tablets NDA #201280 | website=U.S. [[Food and Drug Administration]] (FDA) | date=7 June 2011 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201280Orig1s000TOC.cfm | access-date=3 October 2022 | archive-date=3 April 2022 | archive-url=https://web.archive.org/web/20220403111238/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201280Orig1s000TOC.cfm | url-status=live }}</ref> Jepang, Uni Eropa, Kanada, dan Australia pada tahun 2011.<ref name=AHFS2019>{{cite web |title=Linagliptin Monograph for Professionals |url=https://www.drugs.com/monograph/linagliptin.html |website=Drugs.com |publisher=American Society of Health-System Pharmacists |access-date=6 April 2019 |archive-date=6 April 2019 |archive-url=https://web.archive.org/web/20190406231038/https://www.drugs.com/monograph/linagliptin.html |url-status=live }}</ref><ref>{{cite web | title=10 years | website=Boehringer Ingelheim Limited | url=https://pro.boehringer-ingelheim.com/products/trajenta/10years#pre2011 | access-date=3 October 2022 | archive-date=3 October 2022 | archive-url=https://web.archive.org/web/20221003180613/https://pro.boehringer-ingelheim.com/products/trajenta/10years#pre2011 | url-status=live }}</ref>
==Penamaan==
Linagliptin adalah [[Nama Generik Internasional]] (INN).<ref name="INN">{{cite web |title=International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary names: List 61 |url=https://www.who.int/medicines/publications/druginformation/innlists/RL61.pdf |publisher=World Health Organization |access-date=10 November 2016 |page=66 |archive-date=3 October 2020 |archive-url=https://web.archive.org/web/20201003141721/https://www.who.int/medicines/publications/druginformation/innlists/RL61.pdf |url-status=live }}</ref> Nama merek: Trajenta,<ref>{{cite web | title=Linagliptin: medicine to treat type 2 diabetes | website=NHS UK| date=25 March 2022|url=https://www.nhs.uk/medicines/linagliptin/ | access-date=21 November 2022}}</ref> dll.
==Kegunaan dalam medis==
Linagliptin diindikasikan sebagai tambahan diet dan olahraga untuk meningkatkan kontrol glikemik pada orang dewasa dengan diabetes melitus tipe 2.<ref name="Tradjenta FDA label" />
==Efek samping==
Linagliptin dapat menyebabkan nyeri sendi yang parah.<ref name="Tradjenta FDA label" /><ref>{{cite web|title=DPP-4 Inhibitors for Type 2 Diabetes: Drug Safety Communication - May Cause Severe Joint Pain|url=https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-dpp-4-inhibitors-type-2-diabetes-may-cause-severe-joint-pain|website=U.S. Food and Drug Administration (FDA)|access-date=1 September 2015|date=28 August 2015|archive-date=13 December 2019|archive-url=https://web.archive.org/web/20191213203243/https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-dpp-4-inhibitors-type-2-diabetes-may-cause-severe-joint-pain|url-status=live}}</ref>
==Mekanisme kerja==
==Referensi==
{{Reflist}}
==Pranala luar==
{{Commons category}}
[[Kategori:Turunan alkuna]]
[[Kategori:Obat yang dikembangkan oleh Boehringer Ingelheim]]
[[Kategori:Penghambat dipeptidil peptidase-4]]
[[Kategori:Obat yang dikembangkan oleh Eli Lilly and Company]]
[[Kategori:Piperidina]]
[[Kategori:Kuinazolina]]
[[Kategori:Xantina]]
| |||